home / stock / mbio / mbio news

MBIO News and Press, Mustang Bio Inc. From 04/21/22

Stock Information
Company Name: Mustang Bio Inc.
Stock Symbol: MBIO
Market: NASDAQ
Website: mustangbio.com
Menu
MBIO MBIO Quote MBIO Short MBIO News MBIO Articles MBIO Message Board
Get MBIO Alerts

News, Short Squeeze, Breakout and More Instantly...
MBIO - Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
MBIO - Mustang Bio plans to start phase 1 trial of combo therapy for brain cancer

Mustang Bio (NASDAQ:MBIO) said plans to begin a phase 1 trial combining CAR T cells and oncolytic virus to treat recurrent glioblastoma (rGBM), a type of brain cancer. The company said its decision was supported by interim data from two ongoing phase 1 trials evaluating two candidates, MB-108...

MBIO - Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13R?2-targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma

MB‐101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) are well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials Data support potential of MB-109, the combination of MB-101 + MB-108, to optimize treatment ...

MBIO - Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
MBIO - Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today ann...

MBIO - Mustang Bio surges as Cantor views 2022 "as a year for execution"

Clinical-stage biotech, Mustang Bio (MBIO +25.8%), has recorded the sharpest intraday gain in more than two years Thursday despite reporting lower than expected financials for 4Q 2021. After the earnings, Cantor Fitzgerald noted that 2022 could be a “year of execution” for ...

MBIO - Mustang Bio GAAP EPS of -$0.76 misses by $0.03

Mustang Bio press release (NASDAQ:MBIO): FY GAAP EPS of -$0.76 misses by $0.03. As of December 31, 2021, Mustang’s cash and cash equivalents and restricted cash totaled $110.6 million, compared to $98.8 million as of December 31, 2020, an increase of $11.8 million year-to-date. Shares ...
MBIO - Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...

MBIO - Mustang Bio to Participate in Three March 2022 Investor Conferences

WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, s...

MBIO - Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children's Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
Previous 10 Next 10